- Nexalin Technology (NXL, Financial) restructures Scientific Advisory Board with experts in neurology and neuroimaging.
- Promising data on DIFS™ technology suggests potential in Alzheimer's treatment.
- New Alzheimer's-focused clinical studies set to begin in Q3 2025.
Nexalin Technology, Inc. (NXL) has reconstituted its Scientific Advisory Board (SAB) to advance its Alzheimer's disease program, appointing Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer as new members. This strategic move aims to leverage their expertise in neurology, neuroimaging, and neurodegenerative diseases to guide the company's clinical development of its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology.
Nexalin's DIFS™ technology, delivered via the Gen-2 SYNC and Gen-3 Halo™ headsets, represents a novel approach that may promote neuroplasticity and functional recovery in deep brain structures linked to memory and executive function. Encouraging preclinical and early-stage human data have prompted the company to sharpen its focus on Alzheimer's, with plans for new clinical studies in Q3 2025 incorporating cognitive testing, imaging biomarkers, and MEG-guided metrics.
Dr. Mingxiong Huang is a distinguished expert in magnetoencephalography (MEG) and neuroimaging, with significant contributions to brain imaging biomarkers. Dr. Abe Scheer brings extensive experience in neurology and psychiatry, specializing in neuromodulation therapies. Dr. David Owens, with a background in neuroradiology, leads as the company's Chief Medical Officer, offering insights into advanced imaging techniques.
"This enhanced advisory board reflects our sharpened focus on Alzheimer’s disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda," said Mark White, CEO of Nexalin Technology. "Their combined contributions will be invaluable as we advance Nexalin’s technology through clinical trials designed to address one of the greatest public health challenges of our time."
The restructuring of the SAB underscores Nexalin's commitment to advancing scientific research and developing innovative, non-pharmacological approaches to treating Alzheimer's and related disorders.
